Assessing pain after cancer treatment

Nina Lykkegaard Gehr; Kristine Bennedsgaard; Lise Ventzel; Nanna Brix Finnerup

doi:10.1515/sjpain-2022-0093

Assessing pain after cancer treatment

Nina Lykkegaard Gehr
, Kristine Bennedsgaard
, Lise Ventzel
, Nanna Brix Finnerup^*

^*Kontaktforfatter

IRS - Sygehus Lillebælt, Forskningsenhed for Onkologi (Vejle)

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

64 Downloads (Pure)

Abstract

Objectives: Chronic pain is common following cancer treatment. This is a brief discussion of pain assessment after cancer treatment. Methods: Summary of a lecure for the SASP (Scandinavian Journal of Pain) annual meeting 2022. Results: Assessment of pain involves identifying the presence of pain, its underlying cause, its impact as well as underlying mechanisms. Conclusions: Detailed pain assessment is important for the clinic and for epidemiological and mechanistic studies as well as pain treatment studies.

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Pain
Vol/bind	22
Udgave nummer	4
Sider (fra-til)	676-678
ISSN	1877-8860
DOI	https://doi.org/10.1515/sjpain-2022-0093
Status	Udgivet - 26. okt. 2022

Bibliografisk note

Funding Information:
Research funding: This work was supported by the Lundbeck Foundation R359-2020-2620 and the NovoNordic Foundation NNF20OC0065520. The funding sources had no involvement in the conduct of the study, manuscript preparation, or decision to publish.

Funding Information:
Competing interests: The authors declare no conflict of interest. Outside the submitted work, NBF reports personal fees from NeuroPN, Novartis Pharma, Vertex, and Nanobiotix and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work and has received a grant from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public-private consortium and the companies involved are: Grünenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work.

Publisher Copyright:
© 2022

Finansiering

Research funding: This work was supported by the Lundbeck Foundation R359-2020-2620 and the NovoNordic Foundation NNF20OC0065520. The funding sources had no involvement in the conduct of the study, manuscript preparation, or decision to publish. Competing interests: The authors declare no conflict of interest. Outside the submitted work, NBF reports personal fees from NeuroPN, Novartis Pharma, Vertex, and Nanobiotix and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work and has received a grant from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public-private consortium and the companies involved are: Grünenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work.

Dokumenter og links

10.1515/sjpain-2022-0093

Open Access VersionForlagets udgivne version, 335 KB

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

@article{7ecdd7071ee348928d0359de93f0aca2,

title = "Assessing pain after cancer treatment",

abstract = "Objectives: Chronic pain is common following cancer treatment. This is a brief discussion of pain assessment after cancer treatment. Methods: Summary of a lecure for the SASP (Scandinavian Journal of Pain) annual meeting 2022. Results: Assessment of pain involves identifying the presence of pain, its underlying cause, its impact as well as underlying mechanisms. Conclusions: Detailed pain assessment is important for the clinic and for epidemiological and mechanistic studies as well as pain treatment studies.",

keywords = "cancer, chemotherapy, chronic pain, neuropathy, pain, surgery, Chronic Pain/therapy, Humans, Pain Management, Neoplasms/complications, Pain Measurement",

author = "Gehr, \{Nina Lykkegaard\} and Kristine Bennedsgaard and Lise Ventzel and Finnerup, \{Nanna Brix\}",

note = "Funding Information: Research funding: This work was supported by the Lundbeck Foundation R359-2020-2620 and the NovoNordic Foundation NNF20OC0065520. The funding sources had no involvement in the conduct of the study, manuscript preparation, or decision to publish. Funding Information: Competing interests: The authors declare no conflict of interest. Outside the submitted work, NBF reports personal fees from NeuroPN, Novartis Pharma, Vertex, and Nanobiotix and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work and has received a grant from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public-private consortium and the companies involved are: Gr{\"u}nenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work. Publisher Copyright: {\textcopyright} 2022 ",

year = "2022",

month = oct,

day = "26",

doi = "10.1515/sjpain-2022-0093",

language = "English",

volume = "22",

pages = "676--678",

journal = "Scandinavian Journal of Pain",

issn = "1877-8860",

publisher = "De Gruyter",

number = "4",

}

TY - JOUR

T1 - Assessing pain after cancer treatment

AU - Gehr, Nina Lykkegaard

AU - Bennedsgaard, Kristine

AU - Ventzel, Lise

AU - Finnerup, Nanna Brix

N1 - Funding Information: Research funding: This work was supported by the Lundbeck Foundation R359-2020-2620 and the NovoNordic Foundation NNF20OC0065520. The funding sources had no involvement in the conduct of the study, manuscript preparation, or decision to publish. Funding Information: Competing interests: The authors declare no conflict of interest. Outside the submitted work, NBF reports personal fees from NeuroPN, Novartis Pharma, Vertex, and Nanobiotix and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work and has received a grant from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public-private consortium and the companies involved are: Grünenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work. Publisher Copyright: © 2022

PY - 2022/10/26

Y1 - 2022/10/26

N2 - Objectives: Chronic pain is common following cancer treatment. This is a brief discussion of pain assessment after cancer treatment. Methods: Summary of a lecure for the SASP (Scandinavian Journal of Pain) annual meeting 2022. Results: Assessment of pain involves identifying the presence of pain, its underlying cause, its impact as well as underlying mechanisms. Conclusions: Detailed pain assessment is important for the clinic and for epidemiological and mechanistic studies as well as pain treatment studies.

AB - Objectives: Chronic pain is common following cancer treatment. This is a brief discussion of pain assessment after cancer treatment. Methods: Summary of a lecure for the SASP (Scandinavian Journal of Pain) annual meeting 2022. Results: Assessment of pain involves identifying the presence of pain, its underlying cause, its impact as well as underlying mechanisms. Conclusions: Detailed pain assessment is important for the clinic and for epidemiological and mechanistic studies as well as pain treatment studies.

KW - cancer

KW - chemotherapy

KW - chronic pain

KW - neuropathy

KW - pain

KW - surgery

KW - Chronic Pain/therapy

KW - Humans

KW - Pain Management

KW - Neoplasms/complications

KW - Pain Measurement

U2 - 10.1515/sjpain-2022-0093

DO - 10.1515/sjpain-2022-0093

M3 - Journal article

C2 - 35934881

AN - SCOPUS:85135853984

SN - 1877-8860

VL - 22

SP - 676

EP - 678

JO - Scandinavian Journal of Pain

JF - Scandinavian Journal of Pain

IS - 4

ER -

Assessing pain after cancer treatment

Abstract

Bibliografisk note

Finansiering

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater